三叶青散结抗癌方对三阴性乳腺癌新辅助化疗患者病理完全缓解率的影响  

Effect of Sanyeqing Sanjie Kang' ai Formula on Pathological Complete Response Rates in Triple-Negative Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

作　　者：吕晓皑[1] 王蓓[1] 陈建彬[2] 叶荆[2] 

机构地区：[1]浙江中医药大学附属第一医院,浙江省杭州市邮电路54号310006 [2]浙江中医药大学第一临床医学院

出　　处：《中医杂志》2014年第23期2016-2019,共4页Journal of Traditional Chinese Medicine

基　　金：浙江省自然科学基金资助项目(LY12H29004)

摘　　要：目的观察三叶青散结抗癌方对三阴性乳腺癌(TNBC)新辅助化疗后病理完全缓解率影响及相关因素。方法 107例TNBC患者随机分为治疗组(55例)和对照组(52例),对照组予FEC(5-氟尿嘧啶500 mg/m2+表阿霉素90 mg/m2+环磷酰胺600 mg/m2)或TEC(多西他赛75 mg/m2+表阿霉素60 mg/m2+环磷酰胺500 mg/m2)方案化疗,每21天1次;治疗组于每次化疗后第3天开始服用三叶青散结抗癌方,每日1剂,连服2周。于治疗前,第2、4周期化疗后行乳房彩超、核磁共振增强扫描;并于第4周期化疗后2周行手术,单因素分析治疗组病理完全缓解率与临床病理学指标、分子病理学指标的相关性。结果 FEC方案新辅助化疗4周期后,治疗组病理完全缓解率为30.43%,对照组为4.76%,治疗组明显优于对照组(P<0.05)。TEC方案新辅助化疗4周期后,治疗组病理完全缓解率为31.25%,对照组为9.68%,治疗组明显优于对照组(P<0.05)。单因素分析结果提示,治疗组CK5/6、BRCA1与病理完全缓解率呈正相关(P<0.05)。结论三叶青散结抗癌方能有效提高TNBC新辅助化疗病理完全缓解率,对CK5/6阳性、BRCA1突变者疗效更佳。Objective To observe clinical efficacy and related factors of pathological complete response （pCR） rates in tiple-negative breast cancer （TNBC） patients using Sanyeqing Sanfie Kang＇ ai Formula after neoadjuvant chemotherapy. Methods Totally 107 TNBC patients were randomly divided into treatment group of 55 cases and control group of 52 cases. Control group was treated with FEC regimen, i. e. 5-fluorouracil 500 mg/m2 ＋ epirubicin 90 mg/m2 ＋ cyclophosphamide 600 mg/m2, or TEC regimen, i. e. docetaxel 75 mg/m2 ＋ epirufiicin 60 mg/m2 ＋ cy- clophosphamide 500 mg/m2, once every 21 days. Treatment group took Sanyeqing Sanfie Kang＇ai Formula three days after every round of chemotherapy, 1 dose per day, for 2 weeks. Patients underwent breasts ultrasound and magnetic resonance enhanced scan before treatment and after the 2nd and 4th cycle of chemo. Surgery was done after 2 weeks of the 4th cycle of chemotherapy. Then we make assessment of pCR rates and analyze the correlation of pCR rates with clinical, molecular pathological indicators Results After 4 weeks of FEC regimen neoadjuvant chemotherapy, treatment group＇s pCR rate was 30.43% , superior to 4. 76% of the control group （P 〈0.05）. After 4 weeks of TEC regimen neoadjuvant chemotherapy, treatment group＇s pCR rate was 31.25%, superior to 9.68% of the control group （P 〈 0. 05 ）. Single faetor analysis showed that CK5/6 positive and breast eancer 1 correlated positively with pCR in treatment group （P 〈 0. 05）. Conclusion Sanyeqing Sanjie Kang＇ai Formula can improve TNBC patients＇ pCR afterneoadjuvant chemotherapy effectively and performs better on patients with CK5/6 positive and breast cancer 1 mutation.

关 键 词：三叶青散结抗癌方 三阴性乳腺癌 新辅助化疗 BRCA1突变 CK5/6 

分 类 号：R737.9[医药卫生—肿瘤]